Multidrug-resistant Gram-negative infections: the use of colistin

References

• Wadl M, Heckenbach K, Noll I et al. Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German University Hospitals, 2002–2006. Infection38, 47–51 (2010).
   PubMed Web of Science ®Google Scholar
• Samuelsen O, Toleman MA, Sundsfjord A et al. Molecular epidemiology of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob. Agents Chemother.54(1), 346–352 (2010).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents35(3), 240–243 (2010).
   PubMed Web of Science ®Google Scholar
• Kohlenberg A, Schwab F, Meyer E, Behnke M, Geffers C, Gastmeier P. Regional trends in multidrug-resistant infections in German intensive care units: a real-time model for epidemiological monitoring and analysis. J. Hosp. Infect.73(3), 239–245 (2009).
   PubMedGoogle Scholar
• Hoban DJ, Bouchillon SK, Hawser SP, Badal RE. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn. Microbiol. Infect. Dis.66(1), 78–86 (2010).
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin. Pharmacother.11(5), 779–788 (2010).
   PubMed Web of Science ®Google Scholar
• Mesaros N, Nordmann P, Plésiat P et al.Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect.13(6), 560–578 (2007).
   PubMed Web of Science ®Google Scholar
• McGowan JE Jr. Resistance in nonfermenting Gram-negative bacteria: multidrug resistance to the maximum. Am. J. Infect. Control.34(5 Suppl. 1), S29–S37 (2006).
   PubMed Web of Science ®Google Scholar
• Butler MS, Buss AD. Natural products – the future scaffolds for novel antibiotics? Biochem. Pharmacol.71, 919–929 (2006).
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit. Care Clin.24(2), 377–391 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care10(1), R27 (2006).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents35(2), 194–199 (2010).
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J. Colistin in the 21st Century. Curr. Opin Infect. Dis.22(6), 535–543 (2009).
   PubMed Web of Science ®Google Scholar
• Sarkar S, DeSantis ER, Kuper J. Resurgence of colistin use. Am. J. Health Syst. Pharm.64(23), 2462–2466 (2007).
   PubMed Web of Science ®Google Scholar
• Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J. Antimicrob. Chemother.39(2), 255–260 (1997).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin. Med. Res.4(2), 138–146 (2006).
   PubMedGoogle Scholar
• Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, Baziaka F, Karagianni V, Giamarellou H. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii.Diagn. Microbiol. Infect. Dis.57, 419–422 (2007).
   PubMed Web of Science ®Google Scholar
• Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother.45(3), 781–785 (2001).
   PubMed Web of Science ®Google Scholar
• Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun.64(12), 4922–4927 (1996).
   PubMed Web of Science ®Google Scholar
• Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti Infect. Ther.5, 811–821 (2007).
   PubMed Web of Science ®Google Scholar
• Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann. Pharmacother.33, 960–967 (1999).
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii.Antimicrob. Agents Chemother.51, 3471–3484 (2007).
   PubMed Web of Science ®Google Scholar
• Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case–control study. Crit. Care Med.36(3), 807–811 (2008).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa.J. Chemother.15(3), 235–238 (2003).
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents25, 11–25 (2005).
   PubMed Web of Science ®Google Scholar
• Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of colistin (polymyxin E) against 3,480 isolates of Gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007–2008. Antimicrob. Agents Chemother.53(11), 4924–4926 (2009).
   PubMed Web of Science ®Google Scholar
• Galani I, Kontopidou F, Souli M et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int. J. Antimicrob. Agents31(5), 434–439 (2008).
   PubMed Web of Science ®Google Scholar
• Lo-Ten-Foe JR, de Smet AM, Diederen BM, Kluytmans JA, van Keulen PH. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob. Agents Chemother.51(10), 3726–3730 (2007).
   PubMed Web of Science ®Google Scholar
• Tan TY, Ng LS. Comparison of three standardized disc susceptibility testing methods for colistin. J. Antimicrob. Chemother.58(4), 864–867 (2006).
   PubMed Web of Science ®Google Scholar
• Tan TY, Ng SY. Comparison of Etest, VITEK and agar dilution for susceptibility testing of colistin. Clin. Microbiol. Infect.13(5), 541–544 (2007).
   PubMed Web of Science ®Google Scholar
• Somily AM. Comparison of E-test and disc diffusion methods for the in vitro evaluation of the antimicrobial activity of colistin in multi-drug resistant Gram-negative bacilli. Saudi Med. J.31(5), 507–511 (2010).
   PubMedGoogle Scholar
• Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect.11(2), 115–121 (2005).
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob. Agents Chemother.53(8), 3430–3436 (2009).
   PubMed Web of Science ®Google Scholar
• Papagelopoulos PJ, Mavrogenis AF, Giannitsioti E, Kikilas A, Kanellakopoulou K, Soucacos PN. Management of a multidrug-resistant Pseudomonas aeruginosa infected total knee arthroplasty using colistin. A case report and review of the literature. J. Arthroplasty22(3), 457–463 (2007).
   PubMedGoogle Scholar
• Westerman EM, Le Brun PPH, Touw DJ, Frijlink HW, Heijerman HGM. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J. Cyst. Fibros.3, 23–28 (2004).
   PubMedGoogle Scholar
• Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents26(6), 504–507 (2007).
   Google Scholar
• Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.Clin. Infect. Dis.37(11), e154–e160 (2003).
   PubMed Web of Science ®Google Scholar
• Kohlenberg A, Weitzel-Kage D, van der Linden P et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit. J. Hosp. Infect.74(4), 350–357 (2010).
   PubMedGoogle Scholar
• Glupczynski Y, Bogaerts P, Deplano A et al. Detection and characterization of class A extended-spectrum-β-lactamase-producing Pseudomonas aeruginosa isolates in Belgian hospitals. J. Antimicrob. Chemother.65(5), 866–871 (2010).
   PubMed Web of Science ®Google Scholar
• Viedma E, Juan C, Acosta J et al. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum β-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother.53(11), 4930–4933 (2009).
   PubMed Web of Science ®Google Scholar
• Rosanova M, Epelbaum C, Noman A et al. Use of colistin in a pediatric burn unit in Argentina. J. Burn Care Res.30(4), 612–615 (2009).
   PubMedGoogle Scholar
• Montero M, Horcajada JP, Sorlí L et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection37(5), 461–465 (2009).
   PubMed Web of Science ®Google Scholar
• Sabuda DM, Laupland K, Pitout J et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa.Can. J. Infect. Dis. Med. Microbiol.19(6), 413–418 (2008).
   PubMedGoogle Scholar
• Kallel H, Hergafi L, Bahloul M et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study. Intensive Care Med.33(7), 1162–1167 (2007).
   PubMed Web of Science ®Google Scholar
• Rios FG, Luna CM, Maskin B et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur. Respir. J.30(2), 307–313 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Agrafiotis M, Athanassa Z, Siempos II. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev. Anti Infect. Ther.6(4), 447–452 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant Gram (-) nosocomial pneumonia: a case series. Respir. Med.103(5), 707–713 (2009).
   PubMed Web of Science ®Google Scholar
• Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg. Infect. (Larchmt)9(2), 153–160 (2008).
   PubMedGoogle Scholar
• Nasnas R, Saliba G, Hallak P. [The revival of colistin: an old antibiotic for the 21st Century]. Pathol. Biol. (Paris)57(3), 229–235 (2009).
   PubMedGoogle Scholar
• Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect.14(9), 816–827 (2008).
   PubMed Web of Science ®Google Scholar
• Yakupogullari Y, Otlu B, Dogukan M et al. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.Am. J. Infect. Control36(10), e13–e18 (2008).
   Google Scholar
• Santamaría C, Mykietiuk A, Temporiti E, Stryjewski ME, Herrera F, Bonvehi P. Nephrotoxicity associated with the use of intravenous colistin. Scand. J. Infect. Dis.41(10), 767–769 (2009).
   PubMed Web of Science ®Google Scholar
• Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int. J. Antimicrob. Agents35(3), 297–300 (2010).
   PubMed Web of Science ®Google Scholar
• Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther.30(1), 143–151 (2008).
   PubMed Web of Science ®Google Scholar
• Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int. J. Infect. Dis.11(5), 402–406 (2007).
   PubMed Web of Science ®Google Scholar
• Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int. J. Antimicrob. Agents34(5), 434–438 (2009).
   PubMed Web of Science ®Google Scholar
• Keen EF 3rd, Robinson BJ, Hospenthal DR et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns36(6), 819–825 (2010).
   PubMed Web of Science ®Google Scholar
• Monterrubio-Villar J, González-Velasco C, Valdezate-Ramos S et al. Outbreak of multiresistant Acinetobacter baumannii in a polyvalent intensive care unit: clinical, epidemiological analysis and PFGE-printing evolution. Eur. J. Clin. Microbiol. Infect. Dis.28(10), 1281–1284 (2009).
   PubMed Web of Science ®Google Scholar
• Touati A, Achour W, Cherif A et al. Outbreak of Acinetobacter baumannii in a neonatal intensive care unit: antimicrobial susceptibility and genotyping analysis. Ann. Epidemiol.19(6), 372–378 (2009).
   PubMedGoogle Scholar
• Jean SS, Hsueh PR, Lee WS et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int. J. Antimicrob. Agents33(3), 266–271 (2009).
   PubMed Web of Science ®Google Scholar
• Canduela MJ, Gallego L, Sevillano E, Valderrey C, Calvo F, Pérez J. Evolution of multidrug-resistant Acinetobacter baumannii isolates obtained from elderly patients with respiratory tract infections. J. Antimicrob. Chemother.57(6), 1220–1222 (2006).
   PubMedGoogle Scholar
• Gordona NC, Warehamab DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int. J. Antimicrob. Agents35(3), 219–226 (2010).
   PubMedGoogle Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.Clin. Infect. Dis.43(Suppl. 2), S49–S56 (2006).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother.61(2), 417–420 (2008).
   PubMed Web of Science ®Google Scholar
• Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.J. Infect.53(4), 274–278 (2006).
   PubMed Web of Science ®Google Scholar
• Maviglia R, Nestorini R, Pennisi M. Role of old antibiotics in multidrug resistant bacterial infections. Curr. Drug Targets10(9), 895–905 (2009).
   PubMed Web of Science ®Google Scholar
• Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.Antimicrob. Agents Chemother.54(3), 1165–1172 (2010).
   PubMed Web of Science ®Google Scholar
• Cirioni O, Ghiselli R, Orlando F et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit. Care Med.35(7), 1717–1723 (2007).
   PubMed Web of Science ®Google Scholar
• Katsaragakis S, Markogiannakis H, Toutouzas KG et al.Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance. World J. Surg.32(6), 1194–1202 (2008).
   PubMed Web of Science ®Google Scholar
• Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin. Pharmacother.9(4), 587–599 (2008).
   PubMed Web of Science ®Google Scholar
• Routsi C, Pratikaki M, Platsouka E et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection38(3), 173–180 (2010).
   PubMed Web of Science ®Google Scholar
• Mastoraki A, Douka E, Kriaras I, Stravopodis G, Saroglou G, Geroulanos S. Preventing strategy of multidrug-resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units. Eur. J. Cardiothorac. Surg.33(6), 1086–1090 (2008).
   PubMedGoogle Scholar
• Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int. J. Antimicrob. Agents30(6), 525–529 (2007).
   PubMed Web of Science ®Google Scholar
• Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R.Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol.30(7), 666–671 (2009).
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Antoniadou A et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin. Infect. Dis.50(3), 364–373 (2010).
   PubMed Web of Science ®Google Scholar
• Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother.53(5), 1868–1872 (2009).
   PubMed Web of Science ®Google Scholar
• Suh JY, Son JS, Chung DR, Peck KR, Ko KS, Song JH. Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. Antimicrob. Agents Chemother.54(1), 560–562 (2010).
   PubMed Web of Science ®Google Scholar
• Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother.59(4), 786–790 (2007).
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Voulgari E et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case–control study. J. Clin. Microbiol. DOI: 10.1128/JCM.02301-09 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Pintado V, San Miguel LG, Grill F et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J. Infect.56(3), 185–190 (2008).
   PubMed Web of Science ®Google Scholar
• Lu Q, Girardi C, Zhang M et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.Intensive Care Med.36(7), 1147–1155 (2010).
   PubMed Web of Science ®Google Scholar
• Berlana D, Llop JM, Fort E, Badia MB, Jódar R. Use of colistin in the treatment of multiple-drug-resistant Gram-negative infections. Am. J. Health Syst. Pharm.62(1), 39–47 (2005).
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Resp. Med.102, 407–412 (2008).
   PubMed Web of Science ®Google Scholar
• Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin. Microbiol. Infect.16(8), 1230–1236 (2010).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant Gram (-) nosocomial pneumonia: a case series. Respir. Med.103(5), 707–713 (2009).
   PubMed Web of Science ®Google Scholar
• Hoefnagel D, Dammers R, Ter Laak-Poort MP, Avezaat CJ. Risk factors for infections related to external ventricular drainage. Acta Neurochir. (Wien)150, 209–214 (2008).
   PubMed Web of Science ®Google Scholar
• Ng J, Gosbell IB, Kelly JA, Boyle MJ Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J. Antimicrob. Chemother.58(5), 1078–1081 (2006).
   PubMed Web of Science ®Google Scholar
• Cascio A, Conti A, Sinardi L et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int. J. Infect. Dis.14(7), e572–e579 (2010).
   PubMed Web of Science ®Google Scholar
• Rodríguez Guardado A, Blanco A, Asensi V et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J. Antimicrob. Chemother.61, 908–913 (2008).
   PubMed Web of Science ®Google Scholar
• Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J. Clin. Microbiol.43, 4916–4917 (2005).
   PubMed Web of Science ®Google Scholar